PRMT5 and cancer: The silencing of PRMT5 or MEP50 expression with each specific shRNA impaired cell proliferation and the stabilization of the HSP90 client proteins AKT and NEMO in NDRG2low ATL and cancer cell lines, but not in NDRG2-expressing cell lines.